Bemzire EZ 180mg/10mg Tablet

• Treatment of High cholesterol

Every medicine has some side effects that manage on their own as your body gets used to the medicine, but some people may rarely experience severe side effects. In that case, the patient should contact the doctor immediately. Some common side effects of Bemzire EZ 180mg/10mg Tablet include:

• Upper respiratory tract infection
• Cramps
• Increased uric acid level in blood
• Back pain
• Abdominal pain
• Bronchitis (inflammation of the airways)
• Pain in extremity
• Anemia (low number of red blood cells)
• Increased liver enzymes
• Diarrhea
• Joint pain
• Sinus inflammation
• Fatigue
• Influenza

• Take Bemzire EZ 180mg/10mg Tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.
  
  

• Bemzire EZ 180mg/10mg Tablet is a combination of two different medications such as Bempedoic acid (180mg) and Ezetimibe (10mg). This tablet is used to lower cholesterol levels.
• Its active ingredient like Bempedoic acid works by inhibits the action of an enzyme called ATP citrate lyase involved in cholesterol synthesis in the liver. Other component like ezetimibe works to blocks the absorption of cholesterol from the small intestine. These actions together result in lower amounts of cholesterol in the body.
  
  

• Nguyen, H., Akamnonu, I., & Yang, T. (2021). Bempedoic acid: a cholesterol lowering agent with a novel mechanism of action. Expert Review of Clinical Pharmacology, 14(5), 545-551. https://pubmed.ncbi.nlm.nih.gov/33691561/
• Khan, S. U., & Michos, E. D. (2020). Bempedoic acid and ezetimibe–better together. European journal of preventive cardiology, 27(6), 590-592. https://pmc.ncbi.nlm.nih.gov/articles/PMC7203625/
• Rubino, J., MacDougall, D. E., Sterling, L. R., Hanselman, J. C., & Nicholls, S. J. (2021). Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis, 320, 122-128. https://pubmed.ncbi.nlm.nih.gov/33514449/
• Ballantyne, C. M., Banach, M., Mancini, G. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018). Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis, 277, 195-203. https://pubmed.ncbi.nlm.nih.gov/29910030/
• Ballantyne, C. M., Laufs, U., Ray, K. K., Leiter, L. A., Bays, H. E., Goldberg, A. C., ... & Catapano, A. L. (2020). Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. European journal of preventive cardiology, 27(6), 593-603. https://pubmed.ncbi.nlm.nih.gov/31357887/